GlassScriptPhysician profile
Martin D Broff
NPI 1043208192
$2,961.30
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $605 · 2021: $921 · 2022: $911.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $391.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $380.10 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $259.43 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $179.29 | 2020-2021 | |
| Csl Behring | $174.55 | 2019-2022 | |
| Grifols USA, LLC | $172.31 | 2019-2022 | |
| Pfizer INC. | $160.27 | 2019-2022 | |
| Genentech USA, INC. | $158.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.40 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $138.03 | 2020-2022 | |
| Covis Pharma Gmbh | $102.08 | 2021 | |
| Kaleo, INC. | $92.84 | 2019-2022 | |
| Amgen INC. | $91.72 | 2021-2022 | |
| Genzyme Corporation | $87.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $66.06 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $63.02 | 2021-2022 | |
| Octapharma USA, INC. | $44.62 | 2020 | |
| Shire North American Group INC | $43.01 | 2019 | |
| Alk-Abello, INC | $38.20 | 2019 | |
| Merck Sharp & Dohme LLC | $36.52 | 2019 | |
| Pharming Healthcare, INC. | $29.60 | 2022 | |
| Leo Pharma INC. | $25.89 | 2022 | |
| Biocryst US Sales Co., LLC | $23.36 | 2022 | |
| Incyte Corporation | $20.40 | 2021 | |
| Uswm, LLC | $16.86 | 2021 | |
| Abbvie INC. | $16.76 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Broff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.